BIOHAVEN PHARMACEUTICALS

Serial Number 90788388
Registration 6629316
700

Registration Progress

Application Filed
Jun 22, 2021
Under Examination
Approved for Publication
Nov 9, 2021
Published for Opposition
Nov 9, 2021
Registered
Jan 25, 2022

Trademark Image

BIOHAVEN PHARMACEUTICALS

Basic Information

Serial Number
90788388
Registration Number
6629316
Filing Date
June 22, 2021
Registration Date
January 25, 2022
Published for Opposition
November 9, 2021
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 25, 2022
Registration
Registered
Classes
005 042

Rights Holder

Biohaven Therapeutics Ltd.

99
Address
Ritter House, P.O. Box 173
Road Town, Tortola VG1110
VG

Ownership History

Biohaven Therapeutics Ltd.

Original Applicant
99
New Haven, CT

Biohaven Therapeutics Ltd.

Owner at Publication
99
New Haven, CT

Biohaven Therapeutics Ltd.

Original Registrant
99
Road Town, Tortola VG

Legal Representation

Attorney
Monica Riva Talley

USPTO Deadlines

Next Deadline
902 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-01-25)
Due Date
January 25, 2028
Grace Period Ends
July 25, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

22 events
Date Code Type Description Documents
Apr 17, 2023 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Apr 17, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Apr 17, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 17, 2023 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Apr 17, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 23, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Jan 25, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 12, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Nov 9, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 9, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 20, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 6, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 21, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 21, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 21, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 10, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 10, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 10, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 8, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 8, 2021 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Sep 7, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 25, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in Amyotrophic Lateral Sclerosis (ALS), pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in Alzheimer's disease (AD), disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
First Use Anywhere: 20200300
First Use in Commerce: 20200300
Class 042
Pharmaceutical research and development in the fields of headache, facial pain, impulse control disorders, neurological disorders, and neurodegenerative disorders, and consultation provided in conjunction therewith
First Use Anywhere: 20130900
First Use in Commerce: 20130900

Additional Information

Design Mark
The mark consists of the stylized wording "BIOHAVEN PHARMACEUTICALS", with two outlined hexagon shapes positioned above the letter "I" and one outlined hexagon shape positioned below the letter "I", and the wording "PHARMACEUTICALS" appearing in smaller print below the wording "BIOHAVEN".

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"